<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T19:24:07Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/119879" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/119879</identifier><datestamp>2025-12-04T22:33:57Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478917</setSpec><setSpec>col_2072_478931</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:Item id="hdl_2445_119879">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:2445/119879</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Feasibility of Double-Blind Clinical Trials with Oral Diacetylmorphine: A Randomized Controlled Phase II Study in an Inpatient Setting</dc:title>
               <dc:creator>Colom, Joan (Colom Farran)</dc:creator>
               <dc:creator>Casas, Miquel</dc:creator>
               <dc:creator>Pérez de los Cobos Peris, José C.</dc:creator>
               <dc:creator>del Río, Miquel</dc:creator>
               <dc:creator>Roncero, Carlos</dc:creator>
               <dc:creator>Castells, Xavier</dc:creator>
               <dc:creator>Valero, Sergi</dc:creator>
               <dc:creator>Eiroá Orosa, Francisco José</dc:creator>
               <dc:creator>Batlle, Francisca</dc:creator>
               <dc:creator>Trujols i Albet, Joan</dc:creator>
               <dc:subject>Drogoaddicció</dc:subject>
               <dc:subject>Opi</dc:subject>
               <dc:subject>Desintoxicació de les drogues</dc:subject>
               <dc:subject>Drug addiction</dc:subject>
               <dc:subject>Opium</dc:subject>
               <dc:subject>Drug detoxification</dc:subject>
               <dc:description>The aim of this study was to evaluate the feasibility of conducting double-blind controlled randomized clinical trials using twice-a-day immediate-release oral diacetylmorphine (DAM) in heroin-dependent patients, by means of measuring the capacity of oral DAM to block opiate withdrawal and clinicians' ability to distinguish it from morphine and methadone. This was a randomized, phase II, double-blind, multicenter pilot study comparing immediate-release oral DAM, slow-release oral morphine and oral methadone administered twice a day during 10 days. Forty-five heroin-dependent patients were randomly assigned to these three treatment groups in an inpatient regime. Patients were stabilized with a mean of 350 mg (SD = 193) of immediate-release oral DAM, 108 mg (SD = 46.2) of slow-release oral morphine and 40 mg (SD = 17.9) of methadone. No statistically significant differences were found between any studied medication in clinical outcome. Neither patients nor clinicians were able to identify the administered medication. This study shows the feasibility of double-blind clinical trials using b.i.d. immediate-release oral DAM allowing further phase III clinical trials in the process of introducing oral DAM as a medication for heroin-dependent patients not responding to standard maintenance treatments.</dc:description>
               <dc:date>2018-02-15T17:03:53Z</dc:date>
               <dc:date>2018-02-15T17:03:53Z</dc:date>
               <dc:date>2012-10</dc:date>
               <dc:date>2018-02-15T17:03:53Z</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/acceptedVersion</dc:type>
               <dc:relation>Versió postprint del document publicat a: https://doi.org/10.1159/000336849</dc:relation>
               <dc:relation>European Addiction Research, 2012, vol. 18, num. 6, p. 279-287</dc:relation>
               <dc:relation>https://doi.org/10.1159/000336849</dc:relation>
               <dc:rights>(c) Karger, 2012</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>Karger</dc:publisher>
               <dc:source>Articles publicats en revistes (Psicologia Clínica i Psicobiologia)</dc:source>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>